Recent News About Beigene
-
Wang: 'While the incidence of HCC is increasing in China, the treatment landscape has not advanced accordingly'
International biotechnology company BeiGene, which designs and produces oncology medicines, announced that the China National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE) has accepted a supplemental biologics license application for its drug tislelizumab for use in patients with hepatocellular carcinoma (HCC), according to a press release published recently.
-
BeiGene opens innovation center to 'benefit patients globally'
Executives with a Chinese-based biotechnology company announced the launch of an innovation center that could provide new medicines and treatments to millions battling cancer.